Thirona divests retinal AI division to Revenio Group
Thirona, a Dutch company specialising in AI-powered medical lung image analysis, has announced the sale of its Thirona Retina BV division to Icare Finland Oy, a subsidiary of Revenio Group Corporation. This strategic move, finalised on 20 August 2024, allows Thirona to concentrate on its core focus of pulmonary diseases and interventional pulmonology, while positioning its RetCAD™ technology for broader global impact in eye care.
Expanding reach in ophthalmology
RetCAD™, Thirona Retina’s flagship product, is an AI-driven software designed to screen fundus images for diabetic retinopathy, age-related macular degeneration, and glaucoma. The technology has been integrated into Icare’s ILLUME and other retinal screening solutions, gaining traction across Europe and Asia-Pacific.
Mark van Grinsven, Managing Director of Thirona Retina, commented on the acquisition: “After years of research and development, we’ve created a reliable, clinically validated product with a strong market presence. Combining our expertise with iCare’s resources will accelerate the adoption of RetCAD and broaden its impact, transforming eye care on a global scale.” The divestment enables Thirona to sharpen its focus on AI-driven lung imaging for pulmonary precision medicine. Eva van Rikxoort, CEO & Founder of Thirona, said: “This divestment allows Thirona to sharpen its focus on its long-term growth strategy in AI-driven lung imaging for pulmonary precision medicine and fuel new growth in the interventional pulmonology space.”
Thirona’s recent developments in the pulmonary field include FDA 510(k) clearance for its AI-based clinical software, LungQ™ (v3.0.0), and the expansion of its Medical Advisory Board to include experts in interventional pulmonology and bronchoscopy.
This strategic move highlights the growing importance of AI in healthcare, particularly in diagnostic imaging. By joining forces with Icare, a leader in eye care solutions, Thirona Retina’s RetCAD technology is poised to reach a wider patient population.
Eva van Rikxoort, CEO & Founder of Thirona
